DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect
This study has been completed.
Information provided by:
First received: January 19, 2007
Last updated: November 28, 2008
Last verified: November 2008
To assess the effects of Bacillus clausii (Enterogermina®) on fecal microbial flora (using Polymerase Chain Reaction - Denaturing Gradient Gel Electrophoresis - PCR-DGGE - Method) in antibiotic-treated children with complicated acute otitis media or beta-hemolytic streptococcal pharyngo-tonsillitis.
Drug: Bacillus clausii
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
||Evaluation of the Effects of Enterogermina, 2 Billion Bacillus Clausii Spores, on the Intestinal Flora of Children Antibiotic Treated for Bacterial Upper Respiratory Tract Infections: Open, Pilot Study.
Primary Outcome Measures:
- Changes of microbial composition of fecal bacterial flora by PCR-DGGE analysis. [ Time Frame: between samples obtained at baseline and follow-up ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Changes from baseline of body weight [ Time Frame: During the total study period ] [ Designated as safety issue: No ]
- Assessment of abdominal symptoms [ Time Frame: Daily ] [ Designated as safety issue: No ]
- Presence of Bacillus clausii spores in feces [ Time Frame: after heat shock treatment on selective medium. ] [ Designated as safety issue: No ]
- Number and rate of patients with GI symptoms and time to first development of symptoms. [ Time Frame: recorded in a daily diary card for the total study period ] [ Designated as safety issue: No ]
| Study Start Date:
| Primary Completion Date:
||December 2007 (Final data collection date for primary outcome measure)
Enterogermina® vials containing 2×109 spores of polyantibiotic resistant Bacillus clausii (test drug)
Drug: Bacillus clausii
2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
No Intervention: 2
No treatment (reference group)
|Ages Eligible for Study:
||1 Year to 5 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Subjects with persistency of symptoms and requiring antibiotics for bacterial upper respiratory tract infections, i.e. complicated acute otitis media (diagnosed by otoscopic examination) or beta-haemolytic streptococcal pharyngo-tonsillitis (diagnosed by pharyngeal swab and rapid antigen detection test or positive culture);
- Outpatients or patients attending an emergency room for both diagnoses, and inpatients in case of complicated acute otitis media;
- Written informed consent from both parents.
- History of clinically significant chronic diseases, or chronic diseases necessitating the use of continuous drug therapies, or of any disease that may interfere with the successful completion or the objectives of the trial;
- Clinical evidence of relevant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological or of any disease that may interfere with the successful completion or the objectives of the trial;
- Use of antibiotics, prebiotics or probiotics (medications or dietetic supplements) in the last 2 weeks prior to study entry;
- Hypersensitivity to the investigational product;
- Subjects enrolled in another trial in the previous three months.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00424905
|Milan, Italy |
||Georges Paizis, MD
No publications provided
||Medical Affairs Medical Director, Sanofi-aventis administrative office
History of Changes
|Other Study ID Numbers:
||PM_L_0199, EudraCT # : 2006-002482-39
|Study First Received:
||January 19, 2007
||November 28, 2008
||Italy: Ministry of Health
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 05, 2014
Digestive System Diseases
Respiratory Tract Infections
Respiratory Tract Diseases